1696 related articles for article (PubMed ID: 31109652)
21. Dupilumab Treatment in Adults with Moderate-to-Severe Atopic Dermatitis is Efficacious Regardless of Age of Disease Onset: a Post Hoc Analysis of Two Phase 3 Clinical Trials.
Silverberg JI; Boguniewicz M; Hanifin J; Papp KA; Zhang H; Rossi AB; Levit NA
Dermatol Ther (Heidelb); 2022 Dec; 12(12):2731-2746. PubMed ID: 36269503
[TBL] [Abstract][Full Text] [Related]
22. Dupilumab treatment results in early and sustained improvements in itch in adolescents and adults with moderate to severe atopic dermatitis: Analysis of the randomized phase 3 studies SOLO 1 and SOLO 2, AD ADOL, and CHRONOS.
Silverberg JI; Yosipovitch G; Simpson EL; Kim BS; Wu JJ; Eckert L; Guillemin I; Chen Z; Ardeleanu M; Bansal A; Kaur M; Rossi AB; Graham NMH; Patel N; Gadkari A
J Am Acad Dermatol; 2020 Jun; 82(6):1328-1336. PubMed ID: 32135208
[TBL] [Abstract][Full Text] [Related]
23. Infections in Dupilumab Clinical Trials in Atopic Dermatitis: A Comprehensive Pooled Analysis.
Eichenfield LF; Bieber T; Beck LA; Simpson EL; Thaçi D; de Bruin-Weller M; Deleuran M; Silverberg JI; Ferrandiz C; Fölster-Holst R; Chen Z; Graham NMH; Pirozzi G; Akinlade B; Yancopoulos GD; Ardeleanu M
Am J Clin Dermatol; 2019 Jun; 20(3):443-456. PubMed ID: 31066001
[TBL] [Abstract][Full Text] [Related]
24. Dupilumab Significantly Modulates Pain and Discomfort in Patients With Atopic Dermatitis: A Post Hoc Analysis of 5 Randomized Clinical Trials.
Silverberg JI; Simpson EL; Guttman-Yassky E; Cork MJ; de Bruin-Weller M; Yosipovitch G; Eckert L; Chen Z; Ardeleanu M; Shumel B; Hultsch T; Rossi AB; Hamilton JD; Orengo JM; Ruddy M; Graham NMH; Pirozzi G; Gadkari A
Dermatitis; 2021 Oct; 32(1S):S81-S91. PubMed ID: 33165005
[TBL] [Abstract][Full Text] [Related]
25. Dupilumab Improves Asthma and Sinonasal Outcomes in Adults with Moderate to Severe Atopic Dermatitis.
Boguniewicz M; Beck LA; Sher L; Guttman-Yassky E; Thaçi D; Blauvelt A; Worm M; Corren J; Soong W; Lio P; Rossi AB; Lu Y; Chao J; Eckert L; Gadkari A; Hultsch T; Ruddy M; Mannent LP; Graham NMH; Pirozzi G; Chen Z; Ardeleanu M
J Allergy Clin Immunol Pract; 2021 Mar; 9(3):1212-1223.e6. PubMed ID: 33453450
[TBL] [Abstract][Full Text] [Related]
26. Efficacy and safety of dupilumab with concomitant topical corticosteroids in children 6 to 11 years old with severe atopic dermatitis: A randomized, double-blinded, placebo-controlled phase 3 trial.
Paller AS; Siegfried EC; Thaçi D; Wollenberg A; Cork MJ; Arkwright PD; Gooderham M; Beck LA; Boguniewicz M; Sher L; Weisman J; O'Malley JT; Patel N; Hardin M; Graham NMH; Ruddy M; Sun X; Davis JD; Kamal MA; Khokhar FA; Weinreich DM; Yancopoulos GD; Beazley B; Bansal A; Shumel B
J Am Acad Dermatol; 2020 Nov; 83(5):1282-1293. PubMed ID: 32574587
[TBL] [Abstract][Full Text] [Related]
27. Efficacy and Safety of Abrocitinib in Patients with Severe and/or Difficult-to-Treat Atopic Dermatitis: A Post Hoc Analysis of the Randomized Phase 3 JADE COMPARE Trial.
Simpson EL; Silverberg JI; Thyssen JP; Viguier M; Thaçi D; de Bruin-Weller M; Weidinger S; Chan G; DiBonaventura M; Biswas P; Feeney C; Koulias C; Cork MJ
Am J Clin Dermatol; 2023 Jul; 24(4):609-621. PubMed ID: 37213005
[TBL] [Abstract][Full Text] [Related]
28. Efficacy and Safety of Dupilumab Treatment with Concomitant Topical Corticosteroids in Children Aged 6 Months to 5 Years with Severe Atopic Dermatitis.
Paller AS; Pinter A; Wine Lee L; Aschoff R; Zdybski J; Schnopp C; Praestgaard A; Bansal A; Shumel B; Prescilla R; Bastian M
Adv Ther; 2024 Mar; 41(3):1046-1061. PubMed ID: 38194047
[TBL] [Abstract][Full Text] [Related]
29. Tralokinumab Efficacy Over 1 Year in Adults with Moderate-to-Severe Atopic Dermatitis: Pooled Data from Two Phase III Trials.
Simpson EL; Pink AE; Blauvelt A; Gooderham M; Armstrong AW; Worm M; Katoh N; Peris K; Puig L; Barbarot S; Mark T; Steffensen LA; Tindberg AM; Wollenberg A
Am J Clin Dermatol; 2023 Nov; 24(6):939-952. PubMed ID: 37682422
[TBL] [Abstract][Full Text] [Related]
30. Dupilumab Safety and Efficacy up to 1 Year in Children Aged 6 Months to 5 Years with Atopic Dermatitis: Results from a Phase 3 Open-Label Extension Study.
Paller AS; Siegfried EC; Simpson EL; Cork MJ; Sidbury R; Chen IH; Khokhar FA; Xiao J; Dubost-Brama A; Bansal A
Am J Clin Dermatol; 2024 Jul; 25(4):655-668. PubMed ID: 38743155
[TBL] [Abstract][Full Text] [Related]
31. Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: a randomised, placebo-controlled, dose-ranging phase 2b trial.
Thaçi D; Simpson EL; Beck LA; Bieber T; Blauvelt A; Papp K; Soong W; Worm M; Szepietowski JC; Sofen H; Kawashima M; Wu R; Weinstein SP; Graham NM; Pirozzi G; Teper A; Sutherland ER; Mastey V; Stahl N; Yancopoulos GD; Ardeleanu M
Lancet; 2016 Jan; 387(10013):40-52. PubMed ID: 26454361
[TBL] [Abstract][Full Text] [Related]
32. Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials.
Bachert C; Han JK; Desrosiers M; Hellings PW; Amin N; Lee SE; Mullol J; Greos LS; Bosso JV; Laidlaw TM; Cervin AU; Maspero JF; Hopkins C; Olze H; Canonica GW; Paggiaro P; Cho SH; Fokkens WJ; Fujieda S; Zhang M; Lu X; Fan C; Draikiwicz S; Kamat SA; Khan A; Pirozzi G; Patel N; Graham NMH; Ruddy M; Staudinger H; Weinreich D; Stahl N; Yancopoulos GD; Mannent LP
Lancet; 2019 Nov; 394(10209):1638-1650. PubMed ID: 31543428
[TBL] [Abstract][Full Text] [Related]
33. Tralokinumab Plus Topical Corticosteroids as Needed Provides Progressive and Sustained Efficacy in Adults with Moderate-to-Severe Atopic Dermatitis Over a 32-Week Period: An ECZTRA 3 Post Hoc Analysis.
Silverberg JI; Adam DN; Zirwas M; Kalia S; Gutermuth J; Pinter A; Pink AE; Chiricozzi A; Barbarot S; Mark T; Tindberg AM; Weidinger S
Am J Clin Dermatol; 2022 Jul; 23(4):547-559. PubMed ID: 35857179
[TBL] [Abstract][Full Text] [Related]
34. Dupilumab in adolescents with uncontrolled moderate-to-severe atopic dermatitis: results from a phase IIa open-label trial and subsequent phase III open-label extension.
Cork MJ; Thaçi D; Eichenfield LF; Arkwright PD; Hultsch T; Davis JD; Zhang Y; Zhu X; Chen Z; Li M; Ardeleanu M; Teper A; Akinlade B; Gadkari A; Eckert L; Kamal MA; Ruddy M; Graham NMH; Pirozzi G; Stahl N; DiCioccio AT; Bansal A
Br J Dermatol; 2020 Jan; 182(1):85-96. PubMed ID: 31595499
[TBL] [Abstract][Full Text] [Related]
35. Efficacy and Safety of Multiple Dupilumab Dose Regimens in Patients with Moderate-To-Severe Atopic Dermatitis: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials.
Shih YC; Yeh MC; Yang FA; Chen HC
Dermatology; 2022; 238(6):1060-1072. PubMed ID: 35696987
[TBL] [Abstract][Full Text] [Related]
36. Dupilumab Improves General Health-Related Quality-of-Life in Patients with Moderate-to-Severe Atopic Dermatitis: Pooled Results from Two Randomized, Controlled Phase 3 Clinical Trials.
Simpson EL
Dermatol Ther (Heidelb); 2017 Jun; 7(2):243-248. PubMed ID: 28503712
[TBL] [Abstract][Full Text] [Related]
37. Effect of Dupilumab on Laboratory Parameters in Adolescents with Atopic Dermatitis: Results from a Randomized, Placebo-Controlled, Phase 3 Clinical Trial.
Siegfried EC; Bieber T; Simpson EL; Paller AS; Beck LA; Boguniewicz M; Schneider LC; Khokhar FA; Chen Z; Prescilla R; Mina-Osorio P; Bansal A
Am J Clin Dermatol; 2021 Mar; 22(2):243-255. PubMed ID: 33655423
[TBL] [Abstract][Full Text] [Related]
38. Effectiveness and Safety of Long-Term Dupilumab Treatment in Elderly Patients with Atopic Dermatitis: A Multicenter Real-Life Observational Study.
Patruno C; Fabbrocini G; Longo G; Argenziano G; Ferrucci SM; Stingeni L; Peris K; Ortoncelli M; Offidani A; Amoruso GF; Talamonti M; Girolomoni G; Grieco T; Iannone M; Nettis E; Foti C; Rongioletti F; Corazza M; Veneri MD; Napolitano M;
Am J Clin Dermatol; 2021 Jul; 22(4):581-586. PubMed ID: 33725337
[TBL] [Abstract][Full Text] [Related]
39. Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a critical appraisal.
Thomson J; Wernham AGH; Williams HC
Br J Dermatol; 2018 Apr; 178(4):897-902. PubMed ID: 29315479
[TBL] [Abstract][Full Text] [Related]
40. Efficacy and safety of dupilumab for the treatment of moderate-to-severe atopic dermatitis in adults: A pooled analysis of two phase 2 clinical trials.
Tofte SJ; Papp K; Sadick N; Bohnert K; Simpson E; Thaçi D; Bieber T; Blauvelt A; Sofen H; Gooderham M; Chen Z; Gadkari A; Eckert L; Graham NMH; Pirozzi G; Ardeleanu M
J Am Assoc Nurse Pract; 2018 Sep; 30(9):529-541. PubMed ID: 30211823
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
